• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Nameprostate-specific antigen (psa) for management of prostate cancers
Generic Nameprostate-specific antigen (psa) for management of prostate cancers
Regulation Number866.6010
9115 hague rd.
indianapolis, IN 46250
PMA NumberP000027
Supplement NumberS002
Date Received10/11/2002
Decision Date02/24/2003
Product Code
LTJ[ Registered Establishments with LTJ ]
Advisory Committee Immunology
Supplement Typenormal 180 day track
Supplement Reason change design/components/specifications/material
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for design changes to modify the composition and volumes of the reagents, and labeling changes to add claims for the use of lithium and nh4-heparin plasma samples, to eliminate the recommendation for na citrate plasma, and to omit the sample dilution claim. The device, as modified, will be marketed under the trade name elecsys free psa immunoassay and is indicated for the in vitro quantitative determination of free prostate-specific antigen in human serum and plasma. The elecsys free psa immunoassay is indicated for measurement of fpsa in conjunction with the elecsys total psa assay to develop a ratio (%fpsa) of fpsa to tpsa. This ratio is useful when used in conjunction with the elecsys total psa test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (dre) that is not suspicious for prostate cancer and an elecsys total psa value in the range 4 ng/ml to 10 ng/ml. Prostate biopsy is required for the diagnosis of prostate cancer. The electrochemilumi-niscence immunoassay "eclia" is intended for use on the roche diagnostics elecsys 1010 and 2010, and the modular analytics e170 immunoassay analyzers.